CT-based body composition in diffuse large B cell lymphoma patients: changes after treatment and association with survival

Abstract

Purpose Primary purpose was to assess changes of bone mineral density (BMD) in diffuse large B cell lymphoma (DLBCL) patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone R-CHOP (like) chemotherapy regimen. Secondary purposes were to assess other body composition features changes and to assess the association of pre-therapy values and their changes over time with survival. Material and methods Patients selected underwent R-CHOP(like) regimen for DLBCL, and underwent PET-CT before and after treatment. Main clinical data collected included body mass index, date of last follow-up, date of progression, and date of death. From the low-dose CT images, BMD was assessed at the L1 level; the other body composition values, including muscle and fat distribution, were assessed at the L3 level by using a dedicated software. Descriptive statistics were reported as median and interquartile range, or frequencies and percentages. Statistical comparisons of body composition variables between pre- and post-treatment assessments were performed using the Wilcoxon matched pairs signed rank test. Non-normal distribution of variables was tested with the Shapiro–Wilk test. For qualitative variables, the Fisher exact test was used. Log rank test was used to compare survival between different subgroups of the study population defined by specific body composition cutoffs. The significance level was set at p < 0.05. Results Eighty-two patients were included. The mean follow-up was 37.5 ± 21.4 months. A significant difference was found in mean BMD before and after R-CHOP(like) treatment (p < 0.0001). The same trend was observed for mean skeletal muscle area (SMA) (p = 0.004) and mean skeletal muscle index (SMI) (p = 0.006). No significant association was demonstrated between body composition variables, PFS and OS. Conclusion R-CHOP(like) treatment in DLBCL patients was associated with significant reduction of BMD, SMA and SMI.

Machine Learning and Radiomics Analysis for Tumor Budding Prediction in Colorectal Liver Metastases Magnetic Resonance Imaging Assessment

“…So, patients with liver metastases with tumor budding and/or KRAS mutational status [39,40] respond poorly to anti-EGFR therapy [32]. In the context of personalized medicine, this is evident as the possibility to predict several prognostic markers allows us to identify the best treatment for a specific patient [41][42][43][44][45][46]. Radiomics analysis could be a promising tool to evaluate a lesion "virtually", with the possibility to analyze the whole tumor during the disease history to obtain those markers which can affect the treatment choice [47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64][65].…”

Scientific Status Quo of Small Renal Lesions: Diagnostic Assessment and Radiomics

“…In addition, it should be considered that up to 20% of SRMs are benign [15] and that the risk of malignancy rises with increasing size [20][21][22]. For these reasons, an adequate characterization of renal lesions through the different imaging techniques is critical to optimize SRM management and to improve patient outcomes, preserving renal function in the best viable way and avoiding the risk of overtreatment [23][24][25][26][27][28][29][30].…”